Abstract CT128: Preliminary results from a first-in-human phase I/II study of JS212, an EGFR/HER3-targeted bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Shun Lu, Huiping Li, Yinghua Ji, Longhua Sun, Zhangzhou Huang, Huangming Hong, Jianhua Shi, Fangling Ning, Yongmei Yin, Jian Fang, Aobing Bai, Dexuan Zhang, Zhihao Jiang, Qing Yang
Institutions: Shanghai Jiao Tong University, Shanghai Chest Hospital, Peking University, Peking University Cancer Hospital, First Affiliated Hospital of Xinxiang Medical University, First Affiliated Hospital of Nanchang University, Fujian Medical University, Fujian Provincial Cancer Hospital, Sichuan Cancer Hospital, Jiangsu Province Hospital, Junshi Biosciences (China)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154741627